Pharma

Emergent BioSolutions Inc <EBS.N>: Profits of 4 cents per share anticipated for fourth quarter

  • January 27, 2023 03:04 AM PST | Reuters
 Emergent BioSolutions Inc <EBS.N>: Profits of 4 cents per share anticipated for fourth quarter

27 January 2023 11:04 a.m. All figures in US dollars. Emergent BioSolutions Inc is expected to show a decrease in its fourth quarter earnings to 4 cents​ per share according to the mean Refinitiv

Read More...

Marker Therapeutics Inc Filed 1-For-10 Reverse Stock Split

Marker Therapeutics Inc Filed 1-For-10 Reverse Stock Split

  • January 26, 2023 03:29 PM PST | Reuters

Jan 26 (Reuters) - Marker Therapeutics Inc: * MARKER THERAPEUTICS INC - FILED 1-FOR-10 REVERSE STOCK SPLIT, REDUCTION IN TOTAL NUMBER OF AUTHORIZED SHARES OF COMMON STOCK TO 30 MILLION * MARKER

Read More...
Solid Biosciences Inc Files For Resale Of Up To About 12 Million Shares Of Common Stock By Selling Stockholders

Solid Biosciences Inc Files For Resale Of Up To About 12 Million Shares Of Common Stock By Selling Stockholders

  • January 26, 2023 03:19 PM PST | Reuters

Jan 26 (Reuters) - Solid Biosciences Inc: * SOLID BIOSCIENCES INC FILES FOR RESALE OF UP TO ABOUT 12 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Further company coverage:

Read More...
Contrafect Corp Nasdaq Staff Informed Co That Staff Had Determined To Deny Co's Request For Continued Listing On Nasdaq Capital Market

Contrafect Corp Nasdaq Staff Informed Co That Staff Had Determined To Deny Co's Request For Continued Listing On Nasdaq Capital Market

  • January 26, 2023 03:11 PM PST | Reuters

Jan 26 (Reuters) - ContraFect Corp: * CONTRAFECT CORP - ON JAN 20, NASDAQ STAFF INFORMED CO THAT STAFF HAD DETERMINED TO DENY CO'S REQUEST FOR CONTINUED LISTING ON NASDAQ CAPITAL MARKET Further

Read More...
Sana Biotechnology Announces FDA Nod For Human Clinical Trials For Car T Therapy For B-Cell Malignancies

Sana Biotechnology Announces FDA Nod For Human Clinical Trials For Car T Therapy For B-Cell Malignancies

  • January 26, 2023 02:29 PM PST | Reuters

Jan 26 (Reuters) - Sana Biotechnology Inc: * SANA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR SC291, A HYPOIMMUNE-MODIFIED, CD19-TARGETED ALLOGENEIC CAR T THERAPY

Read More...
Kronos Bio Inc Marianne De Backer Notified Decision To Resign From Board

Kronos Bio Inc Marianne De Backer Notified Decision To Resign From Board

  • January 26, 2023 02:24 PM PST | Reuters

Jan 26 (Reuters) - Kronos Bio Inc: * KRONOS BIO INC - ON JAN 21 MARIANNE DE BACKER, NOTIFIED DECISION TO RESIGN FROM BOARD AS A RESULT OF HER APPOINTMENT AS CEO OF VIR BIOTECHNOLOGY * KRONOS BIO INC -

Read More...
FDA Advisers Vote In Favor Of Using Same Coronavirus Variant For Initial COVID Vaccine Doses And Boosters

FDA Advisers Vote In Favor Of Using Same Coronavirus Variant For Initial COVID Vaccine Doses And Boosters

  • January 26, 2023 01:42 PM PST | Reuters

Jan 26 (Reuters) - Moderna Inc: * FDA ADVISERS VOTE IN FAVOR OF USING SAME CORONAVIRUS VARIANT FOR INITIAL COVID VACCINE DOSES AND BOOSTERS Further company coverage:

Read More...
Novavax Official Says needs 6 months to produce annual COVID shots that match new variants

Novavax Official Says needs 6 months to produce annual COVID shots that match new variants

  • January 26, 2023 11:43 AM PST | Reuters

Jan 26 (Reuters) - Moderna Inc: * NOVAVAX OFFICIAL SEEKS SIX MONTH TIME PERIOD FROM PROVIDING COVID STRAIN SELECTION TO DELIVERING PRODUCT * NOVAVAX OFFICIALS TELLS FDA THAT SIX MONTH PERIOD IS

Read More...
Novavax needs 6 months to produce annual COVID shots that match new variants

Novavax needs 6 months to produce annual COVID shots that match new variants

  • January 26, 2023 11:32 AM PST | Reuters

By Leroy Leo (Reuters) - Novavax Inc said on Thursday it would require six months to produce a COVID-19 vaccine designed to match whichever coronavirus variants are circulating for an annual

Read More...
FDA identifies recall of Emergent's decontamination kits as most serious

FDA identifies recall of Emergent's decontamination kits as most serious

  • January 26, 2023 10:06 AM PST | Reuters

(Adds company comments) Jan 26 (Reuters) - The U.S. Food and Drug Administration on Thursday classified the recall of Emergent BioSolutions Inc's skin decontamination lotion kits as the most serious

Read More...
Emergent Says After Becoming Aware That Small Number Of RSDL Packets Had Leaked, Notified U.S. FDA Other Government Agencies, & Customers

Emergent Says After Becoming Aware That Small Number Of RSDL Packets Had Leaked, Notified U.S. FDA Other Government Agencies, & Customers

  • January 26, 2023 08:59 AM PST | Reuters

Jan 26 (Reuters) - Emergent BioSolutions Inc: * EMERGENT SAYS AFTER BECOMING AWARE THAT SMALL NUMBER OF RSDL PACKETS HAD LEAKED, NOTIFIED U.S. FDA OTHER GOVERNMENT AGENCIES, &amp; CUSTOMERS - SPOKESPERSON

Read More...